Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Biochemistry and Biophysics, University of Rochester, Rochester, NY 14642, USA; suresh_desilva@urmc.rochester.edu (S.d.S.).
Since its emergence onto the gene therapy scene nearly 25 years ago, the replication-defective Herpes Simplex Virus Type-1 (HSV-1) amplicon has gained significance as a versatile gene transfer platform due to its extensive transgene capacity, widespread cellular tropism, minimal immunogenicity, and its amenability to genetic manipulation. Herein, we detail the recent advances made with respect to the design of the HSV amplicon, its numerous in vitro and in vivo applications, and the current impediments this virus-based gene transfer platform faces as it navigates a challenging path towards future clinical testing.
Images from this publication.See all images (3) Free text
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on